Treatment with tumor-infiltrating lymphocytes versus ipilimumab for advanced melanoma - report from ESMO2022

from Medical Digest & Congress Report · host Medical Congress News

Professor John Haanen from the Netherlands Cancer Institute presented the first randomized phase 3 trial on treatment with tumor-infiltrating lymphocytes vs. ipilimumab for advanced melanoma at this years ESMO Congress.  Video: https://congressreport.eu/scientific-contents/interview:treatment-tumor-infiltrating-lymphocytes-versus-ipilimumab-advanced-melanoma

Episode metadata supplied by the publisher feed · Published Sep 29, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Treatment with tumor-infiltrating lymphocytes versus ipilimumab for advanced melanoma - report from ESMO2022

0:00 8:59

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 8 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on September 29, 2022.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!